Molecular biologic analyses have become an integral part of diagnostic and follow-up investigation of live threatening malignant and non-malignant diseases, thus completing cytogenetic and immunological investigations.
Our laboratory supports the evaluation of treatment follow-up mainly in patients after allogeneic blood stem cell transplantation. After enrichment of special cellular fractions and cell subpopulations we apply qualitative and quantitative PCR procedures, fragment analysis and nucleotide sequencing.
The focus of our laboratory is the analysis of chimerism after allogeneic stem cell transplantation and the analysis of minimal residual disease (MRD) in patients with acute lymphoblastic leukemia. Both procedures are certified according to DIN EN ISO 15189(Certificate) . The laboratory is certified according to DIN EN ISO 9001:2008, it is member of the Euro-chimerism consortium and member of ESLOH EuroMRD-ALL.
The aim of transplantation is the eradication the recipient’s haematopoietic system and its permanently replacement by the haematopoietic system of the donor. Complete chimerism is established when all haematopoietic cells originate from the donor. In malignant diseases like leukaemia complete chimerism is associated with a lower risk of relapse.
ALL is the most frequent malignant disease in children. The success of treatment is dependent on permanent elimination of leukemic cells below microscopic detection limit.
The standard method for the investigation of BCR-ABL negative ALL is the detection of patient’s leukaemia specific somatically rearranged immunoglobuline (Ig-) and T-cell receptor (TCR) genes. The procedure is divided into 2 steps:
Dr. rer. nat. Hermann Kreyenberg
Phone: +49 (0) 69 6301-6449
Fax: +49 (0) 69 6301-83937
Scientific advice and information
Phone: +49 (0) 69 6301-7542 (Prof. Bader)
Phone: +49 (0) 69 6301-83926
Building 32 A, Second floor